Bisphosphonates in cancer therapy

被引：172

作者：

Stresing, Verena

Daubine, Florence

Benzaid, Ismahene

Moenkkoenen, Hannu

Clezardin, Philippe

机构：

[1] INSERM, Res Unit, U664, Fac Med Laennec, F-69372 Lyon 08, France

[2] Univ Lyon 1, F-69622 Villeurbanne, France

来源：

CANCER LETTERS | 2007年 / 257卷 / 01期

关键词：

bisphosphonate; bone; metastasis; cancer;

D O I：

10.1016/j.canlet.2007.07.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bisphosphonates are the standard of care in the treatment of malignant bone diseases, because of their ability to inhibit osteoclast-mediated bone destruction. We review here preclinical evidence that bisphosphonates also exert direct antitumour effects and antiangiogenic properties. Furthermore, we describe new insights on how bisphosphonates may act synergistically in combination with antineoplastic drugs or gamma delta T cells to exhibit antitumour activity. These findings reveal new exciting possibilities to fully exploit the antitumour potential of bisphosphonates in the clinical practice. (C) 2007 Elsevier Ireland Ltd. All rights reserved.

引用

页码：16 / 35

页数：20

共 143 条

[81] A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates [J].